Filtered By:
Vaccination: Tuberculosis (BCG) Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 192 results found since Jan 2013.
Century-Old TB Vaccine Fails to Protect Against Covid
Early in the pandemic, scientists began testing an old TB vaccine against the coronavirus. But the trial enrolled fewer participants than expected as new Covid vaccines were introduced, and no discernible effect was found.
Source: NYT Health - April 26, 2023 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Coronavirus (2019-nCoV) Vaccination and Immunization Immune System Tuberculosis Clinical Trials New England Journal of Medicine Source Type: news
The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2 – The results of ProBCG: A Multicenter Randomized Clinical Trial in Brazil
At the beginning of the Coronavirus Disease (COVID-19) pandemic [1], caused by severe acute respiratory syndrome Coronavirus (SARS-CoV-2), medical and scientific groups suggested using existing licensed vaccines or drugs to prevent and treat SARS-CoV-2 infection. Without approved, safe, and effective therapeutic options, these efforts could help mitigate the spread, morbidity, mortality, and economic losses consequent to the lethal virus [2].
Source: International Journal of Infectious Diseases - February 23, 2023 Category: Infectious Diseases Authors: Ana Paula Santos, Guilherme Loureiro Werneck, Ana Paula Razal Dalvi, Carla Concei ção dos Santos, Paulo Fernando Guimarães Morando Marzocchi Tierno, Hanna Silva Condelo, Bruna Macedo, Janaina Aparecida de Medeiros Leung, Jeane de Souza Nogueira, Ludmil Tags: Original article - Clinical Trial Source Type: research
Efficacy of Bacillus Calmette –Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial
ConclusionsBCG is protective in reducing the incidence of acute respiratory illness (probable symptomatic COVID-19 infection) and severity of the disease, including hospitalisation, in patients belonging to the high-risk group of COVID-19 infection, and the antibody response persists for quite a long time. A multi-centre study with a larger sample size will help to confirm the findings in this study.Clinical Trials RegistryClinical Trials Registry India (CTRI/2020/07/026668).
Source: Infectious Diseases and Therapy - October 15, 2022 Category: Infectious Diseases Source Type: research
Potential of mRNA vaccines to become versatile cancer vaccines
World J Clin Oncol. 2022 Aug 24;13(8):663-674. doi: 10.5306/wjco.v13.i8.663.ABSTRACTFor centuries, therapeutic cancer vaccines have been developed and tried clinically. Way back in the late 19th century, the Father of Immunotherapy, William Coley had discovered that bacterial toxins were effective for inoperable sarcomas. In the 1970s, the Bacillus Calmette-Guérin (BCG) vaccine was repurposed, e.g., for advanced melanomas. Then, therapeutic cancer vaccines based on tumor-associated antigens (found on the surfaces of cancer cells) were tried clinically but apparently have not made a really significant clinical impact. For ...
Source: Clinical Prostate Cancer - September 26, 2022 Category: Cancer & Oncology Authors: Shiu-Ying Tsao Source Type: research
Assessing the impact of non-pharmaceutical interventions (NPIs) and BCG vaccine cross-protection in the transmission dynamics of SARS-CoV-2 in eastern Africa
The outbreak of the novel coronavirus disease 2019 (COVID-19) is still affecting African countries. The pandemic presents challenges on how to measure governmental, and community responses to the crisis. Beyon...
Source: BMC Research Notes - September 4, 2022 Category: Research Authors: Chelsea Mbeke Kilonzo, Mark Wamalwa, Solange Youdom Whegang and Henri E. Z. Tonnang Tags: Research note Source Type: research
Why a Century-Old Vaccine Offers New Hope Against Pathogens
The B.C.G. tuberculosis vaccine may protect against Covid-19 and other infections by broadly bolstering the immune system.
Source: NYT Health - August 16, 2022 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Clinical Trials Diabetes Vaccination and Immunization Immune System Tuberculosis Coronavirus (2019-nCoV) Source Type: news
Tuberculosis endemicity and BCG vaccination: Protection against COVID-19
This study aimed to assess the effect of tuberculosis (TB) endemicity and Bacille Calmette-Guerin (BCG) coverage on COVID-19. Available data regarding TB incidence, BCG coverage (as per the World Health Organization), and COVID-19 incidence of 168 countries as of 19th September 2021. Countries were divided into four cohorts based upon annual TB incidence and BCG coverage and COVID-19 incidence and case fatality rates were compared using the Kruskal-Wallis test. Countries with low TB incidence and low BCG coverage had the highest COVID-19 incidence per lac population. However, no significant difference was seen in COVID-19 ...
Source: Monaldi Archives for Chest Disease - June 27, 2022 Category: Respiratory Medicine Authors: Tarun Krishna Boppana Saurabh Mittal Karan Madan Anant Mohan Vijay Hadda Randeep Guleria Source Type: research
End-point definition and trial design to advance tuberculosis vaccine development
Tuberculosis (TB) remains a leading infectious cause of death worldwide and the coronavirus disease 2019 pandemic has negatively impacted the global TB burden of disease indicators. If the targets of TB mortality and incidence reduction set by the international community are to be met, new more effective adult and adolescent TB vaccines are urgently needed. There are several new vaccine candidates at different stages of clinical development. Given the limited funding for vaccine development, it is crucial that trial designs are as efficient as possible. Prevention of infection (POI) approaches offer an attractive opportuni...
Source: European Respiratory Review - June 7, 2022 Category: Respiratory Medicine Authors: Garcia-Basteiro, A. L., White, R. G., Tait, D., Schmidt, A. C., Rangaka, M. X., Quaife, M., Nemes, E., Mogg, R., Hill, P. C., Harris, R. C., Hanekom, W. A., Frick, M., Fiore-Gartland, A., Evans, T., Dagnew, A. F., Churchyard, G., Cobelens, F., Behr, M. A. Tags: Reviews Source Type: research
BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents
Int Immunopharmacol. 2022 May 17;108:108870. doi: 10.1016/j.intimp.2022.108870. Online ahead of print.ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), and its variants have brought unprecedented impacts to the global public health system, politics, economy, and other fields. Although more than ten COVID-19 specific vaccines have been approved for emergency use, COVID-19 prevention and control still face many challenges. Bacille Calmette-Guérin (BCG) is the only authorized vaccine used to fight against tuberculosis (TB), it has been hy...
Source: International Immunopharmacology - May 21, 2022 Category: Allergy & Immunology Authors: Wenping Gong Yingqing Mao Yuexi Li Yong Qi Source Type: research
Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques
The tuberculosis vaccine, Bacille Calmette-Guerin (BCG), also affords protection against non-tuberculous diseases attributable to heterologous immune mechanisms such as trained innate immunity, activation of non-conventional T-cells, and cross-reactive adaptive immunity. Aerosol vaccine delivery can target immune responses toward the primary site of infection for a respiratory pathogen. Therefore, we hypothesised that aerosol delivery of BCG would enhance cross-protective action against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and be a deployable intervention against coronavirus disease 2019 (...
Source: Frontiers in Immunology - February 9, 2022 Category: Allergy & Immunology Source Type: research
